The rejection of the bedaquiline patent opposition in Indonesia raises the risk of difficulty in accessing optimal TB therapy
The patent opposition was submitted by the Indonesia AIDS Coalition and Indonesia for Global Justice in November 2022 and was rejected by a decision from the Judiciary Panel on 9 November 2023.
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the TB drug bedaquiline with dispersible tablet formulations. The patent opposition was filed to the Patent Appeal Commission, Directorate General of Intellectual Property (DGIP), Ministry of Law and Human Rights. The patent opposition was submitted in November 2022 and was rejected by a decision from the Judiciary Panel on 9 November 2023.
Read the full press release here.
Source: Make Medicines Affordable
